Dr. Wang manages HUYABIO’s Research and Database group to identify, evaluate and propose novel drug discovery programs originating from China. With over 20 years industrial drug discovery experience focusing on oncology, inflammation and autoimmune diseases, he leverages his expertise, conducting due diligence in coordination with HUYABIO China’s scouting team, to propose drug candidates for in-licensing.
Dr. Shojaei has extensive knowledge in molecular biology, cell biology and translational sciences in small molecule inhibitors and biologics in the biotechnology and pharmaceutical industries. With over 28 years of experience, he previously served as Director, Drug Development and Biology at Zentalis Pharmaceuticals and Sanford Burnham Prebys Medical Discovery Institute, focusing on translational sciences in oncology.
Dr. Tchekanova has extensive experience in the oncology and cardiovascular pharmaceutical industries with global Regulatory Affairs, strategic Quality Assurance and clinical research. With over 25 years experience, she previously served as VP, Regulatory Affairs and Clinical Operations at Statera Biopharmaceutical, providing strategic oversight for the clinical operations, pharmacovigilance, safety reporting and Regulatory operations.
Dr. Romano is responsible for evaluation, preclinical and early clinical development of HUYABIO’s in-licensed drug candidates sourced from China. Having participated in all aspects of HUYABIO’s in-licensing process, including initial assessment, due diligence, partnering agreements, alliance management, and execution of development plans, she is currently responsible for the clinical proof of concept trials for HUYABIO’s lead cardiovascular asset, HBI-3000.
Mr. Davis brings extensive expertise in global marketing, brand development, strategic pricing and contracting, national sales strategy and sales training implementation for oncology brand launches in the biotechnology industry. With over 26 years experience, he most recently served as SVP, Commercial Operations for Secura Bio, where he led global sales, marketing, market access, pricing, and contracting during the commercial launch of duvelisib and panobinostat, and subsequently developed the sales, marketing, clinical affairs and business development departments.
Dr. Riebman has extensive executive expertise in the cardiac pharmaceutical industry with strategic leadership, innovation and commercialization skills. With over 40 years clinical, industry and academic experience, he has served in leadership positions at Aziyo Biologics, Amgen, Novartis Pharmaceuticals and J&J’s Ethicon Biosurgery. Dr. Riebman’s clinical experience focused on Cardiovascular and Thoracic Surgery with heart transplantation and heart assist devices.
Dr. Kemmerer leads the chemistry, manufacturing, and controls functions for HUYABIO’s in-licensed drug candidates, leveraging expertise in formulation and process development, scale-up, tech transfer and manufacturing. With over 25 years of drug development experience in the pharmaceutical/biotech industry, he has held roles of increasing levels of responsibility at Merck and Pfizer on the development and manufacture of a broad range of drug products, including Emend®, Nexium® and Pepcid®.
Dr. Lee has broad expertise in taking products from early clinical development through marketing approval in biotechnology and pharmaceutical organizations. With over 28 years experience developing small molecules into cell-based therapy products, she previously served as Chief Medical Officer at Beyondspring Pharmaceuticals, EVP, Clinical and Medical Affairs at Delcath Systems, and was the first CMO at Kite Pharma.
Mr. Kholos has broad expertise encompassing legal, business, engineering, and operational issues in government, public and private corporate, and law firm environments. With over 25 years experience as a legal, compliance and corporate development professional for life science and technology companies, he previously served as Director of Business Development for Becton Dickinson.
Mr. Wang brings extensive global financial expertise in capital raising, operating companies, and principal investing across the biotech, fintech, and high tech industries. With 25 years experience, he most recently managed a $500M endowment at Scripps Research, and previously served as Chief Financial Officer of Fincera, where he led a successful $70M re-IPO and uplisting to Nasdaq.
